Influence of Decentralization and Type of Patient on Loss to Follow-up among Multidrug-Resistant Tuberculosis Patients in Indonesia from 2014 to 2015
Abstract
Keywords
Full Text:
PDFReferences
1. World Health Organization. Global tuberculosis report 2018. Geneva, Switzerland: World Health Organization; 2018.
2. World Health Organization. WHO _ The top 10 causes of death [Internet]. Geneva, Switzerland: World Health Organization; 2017 [cit- ed 2017 Dec 11]. Available from: http://www.who.int/mediacentre/ factsheets/fs310/en/
3. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan Kementerian Kesehatan Republik Indonesia. Rencana aksi nasional pro- grammatic management of drug resistance tuberculosis pengendalian tuberkulosis Indonesia: 2011-2014. Jakarta: Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan Kementerian Kesehatan Republik Indonesia; 2011.
4. Direktorat Jenderal Pengendalian Penyakit Dan Penyehatan Lingkungan Kementerian Kesehatan Republik Indonesia. Petunjuk teknis manaje- men terpadu pengendalian tuberkulosisi resisten obat. Jakarta: Direktorat Jenderal Pengendalian Penyakit Dan Penyehatan Lingkungan Kementerian Kesehatan Republik Indonesia; 2013.
5. World Health Organization. Multidrug-resistant tuberculosis (MDR- TB) 2014 update. Geneva: World Health Organization Press; 2014.
6. World Health Organization. Global tuberculosis report 2017. Geneva, Switzerland: World Health Organization; 2017.
7. Nurjannah. Update kegiatan program TB [Internet]. 2017 [cited 2017 April 22]. Available from: http://www.tbindonesia.or.id/2017/04/ 18/materi-monev-2017-makasar-10-13-april-2017/
8. Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkunga Kementerian Kesehatan Republik Indonesia. Pedoman nasional pen- gendalian tuberkulosis. Jakarta: Direktorat Jenderal Pengendalian Penyakit dan Penyehatan Lingkungan Kementerian Kesehatan Republik Indonesia; 2014.
9. Franke MF, Appleton SC, Bayona J, Arteaga F, Llaro K, Shin SS, et al. Risk factors and mortality associated with default from multidrug-resis- tant tuberculosis treatment. Clinical Infectious Disease. 2009;46(12):1844–51.
10. Kementrian Kesehatan Republik Indonesia. Buku saku pengendalian TB-RO untuk petugas fasyankes. Jakarta: Kementrian Kesehatan Republik Indonesia; 2014. 1–79 p.
11. Gler MT, Podewils LJ, Munez N, Galipot M, Quelapio MID, Tupasi TE. Impact of patient and program factors on default during treatment of multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease [Internet]. 2012;16(7):955–60. Available from: https://www.ncbi.nlm.nih.gov/pubmed/22584124
12. World Health Organisation. Definitions and reporting framework for tuberculosis–2013 revision [Internet]. Geneva: World Health Organisation; 2014. 9–11 p. Available from: http://apps.who.int/iris/ bitstream/10665/79199/1/9789241505345_eng.pdf?ua=1%0Ahttp:// apps.who.int/iris/bitstream/10665/79199/1/9789241505345_eng.pdf
13. Hastono SP. Analisis data pada bidang kesehataan. 1st ed. Jakarta: Rajawali Pers; 2016.
14. Harlan J. Data kosong dan imputasi ganda. Depok: Gunadarma; 2016.
15. Kleinbaum DG, Klein M. Survival analysis: a self learning text. 3rd ed. Gail M, Krickerberg K, Samet JM, editors. New York: Springer; 2014. 1–700 p.
16. World Health Organization. Roadmap to prevent and combat drug-re- sistant tuberculosis: the consolidated action plan to prevent and combat multidrug- and extensively drug-resistant tuberculosis in the WHO European Region 2011–15. resolution EUR/RC61/R7. Copenhagen, Denmark: World Health Organization; 2011.
17. Kuchukhidze G, Kumar AM V, Colombani P de, Khogali M, Nanava U, Blumberg HM, et al. Risk factors associated with loss to follow-up among multidrug-resistant tuberculosis patients in Georgia. Public Health Action. 2014; 4 (Suppl 2): 541-6.
18. Shringarpure KS, Isaakidis P, Sagili KD, Baxi RK. Loss-to-follow-up on multidrug resistant tuberculosis treatment in Gujarat, India : the when and who of it. PLOS ONE. 2015; 10(7): e0132543.
19. Keshavjee S, Gelmanova IY, Pasechnikov AD, Mishustin SP, Andreev YG, Yedilbayev A, et al. Treating multidrug-resistant tuberculosis in Tomsk, Russia: developing programs that address the linkage between poverty and disease. Annals of The New York Academy of Sciences. 2008;1136:1–11.
20. Toczek A, Cox H, Cros P du, Cooke G, Ford N. Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta- analysis. International Journal of Tuberculosis and Lung Disease [Internet]. 2012; 17 (3): 299–307. Available from: https://www. ncbi.nlm.nih.gov/pubmed/23211716
21. Soepandi PZ. Output of treatment and cost variations of TB - MDR / XDR with PMDT strategy in RSUP Persahabatan. Jurnal Administrasi Kebijakan Kesehatan. 2014;1(1):19–25.
22. Tiemersma EW, Hafidz F. Costs faced by (multidrug resistant) tubercu- losis patients during diagnosis and treatment report from a pilot study in Indonesia [Internet]. 2014. Available from: https://www.chal- lengetb.org/publications/tools/costing/Cost_Faced_by_MDR- TB_Patients_Indonesia.pdf
23. Pinidiyapathirage J, Senaratne W, Wickremasinghe R. Prevalence and predictors of default with tuberculosis treatment in Sri Lanka. Southeast asian Journal of Tropical Medicine and Public Health. 2008;39(6):1076–82.
24. Vijay S, Balasangameswara VH, Jagannatha PS, Saroja VN, Kumar P. Defaults among tuberculosis patients treated under DOTS in Bangalore City: a search for solution. Indian Journal Tuberculosis. 2003;50:185– 95.
25. Muture BN, Keraka MN, Kimuu PK, Kabiru EW, Ombeka VO, Oguya F. Factors associated with default from treatment among tuberculosis patients in Nairobi Province, Kenya : A case control study. BMC Public Health [Internet]. 2011;11(1):696. Available from: http://www.bio- medcentral.com/1471-2458/11/696
26. Finlay A, Lancaster J, Holtz TH, Weyer K, Miranda A, Walt M Van Der. Patient- and provider-level risk factors associated with default from tu- berculosis treatment, South Africa, 2002 : a case control study. BMC Public Health [Internet]. 2012;12(1):56. Available from: http://www.biomedcentral.com/1471-2458/12/56
DOI: http://dx.doi.org/10.21109/kesmas.v13i3.2710
Refbacks
- There are currently no refbacks.